Document is current

Any future updates will be listed below

Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

Crossref DOI link: https://doi.org/10.1007/s13555-025-01420-3

Published Online: 2025-05-07

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark